Suzetrigine in Total Hip Arthroplasty
NCT07226700
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Total Hip Arthroplasty (THA)
- Total Hip Arthroplasty \(THA\)
- Total Hip Replacement
- Total Hip Replacement Surgery
- Total Hip Replacements
- Total Hip Replacement Arthroplasty
- Suzetrigine
- Pain Management
- Pain
- Nav 1.8
- JOURNAVX
- Opioid Cessation
- Opioid Consumption, Postoperative
- Multimodal Analgesia
- Randomized Controlled Trial
- Randomized Controlled Study
- Randomized Controlled Trials
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Hospital for Special Surgery, New York
- Last updated on ClinicalTrials.gov
- July 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Hospital for Special Surgery · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.